Bio-Heart Invests RMB 50M in Cardiotek to Advance Balloon-Expandable TAVR Device
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese interventional cardiovascular device maker,...
Company
HitGen’s Vernalis Subsidiary Collaborates with Unison Medicines on Undruggable Bacterial Target
China’s HitGen Inc. (SHA: 688222) announced a strategic research collaboration between its wholly owned subsidiary,...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19...
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...
CellOrigin and Qilu Partner on Global CAR-iMAC Cancer Therapy Development
CellOrigin Biotech (Hangzhou) Co., Ltd, a China-based biotech firm specializing in allogeneic cell therapies, has...
Bio-Heart Plans STAR Board IPO After Hong Kong Debut to Advance Cardiovascular Therapies
Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185), a leading Chinese innovator in interventional cardiovascular...
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun...
SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC
China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...
Hotgen Biotech Receives UK Approvals for Monkeypox and COVID-19 Antigen Detection Kits
Shanghai-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced significant regulatory milestones in the United...
Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up...
CanSino, Livzon Win China EUAs for COVID-19 Booster Vaccines
China-based vaccine makers CanSino Biologics (HKG: 6185) and Livzon Pharmaceutical Group Inc. (HKG: 1513) have...
AWS Partners with Zhongshan to Launch Smart Manufacturing and Biomedical Digital Center
Amazon Web Services (AWS) and Zhongshan’s Bureau of Commerce announced a partnership at the China...
BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion
China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300...
Zelgen Biopharmaceuticals’ Jacktinib Wins FDA Approval for Severe Alopecia Areata
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) secured U.S. FDA approval to launch a clinical...
Jacobio Pharmaceuticals Doses First Patient in JAB-BX102 Phase I/IIa Trial for CD73-Targeted Cancer Therapy
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) announced the first patient dosed in a...
Northeast Pharma Licenses MedAbome’s MAb11-22.1 for ADC and CAR-T Development
China’s Northeast Pharmaceutical Co., Ltd (SHE: 000597) has signed a licensing agreement with U.S.-based MedAbome...
Alphamab Oncology Highlights KN046, KN026 Advances at ESMO 2022
China’s Alphamab Oncology (HKG: 9966) will present updated clinical data for its bispecific antibody candidates...
AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease
UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...